Central Nervous System Therapeutics Market Size, Share, Trends, & Industry Analysis Report, By Disease (Neurovascular Disease, CNS Trauma, Mental Health), By Drug Class, By Distribution Channel, and By Region – Market Forecast, 2025–2034
- Published Date:Jul-2025
- Pages: 125
- Format: PDF
- Report ID: PM5368
- Base Year: 2024
- Historical Data: 2020-2023
Market Overview
The global central nervous system therapeutics market was valued at USD 123.39 billion in 2024 and is expected to grow at a CAGR of 7.6% from 2025 to 2034. The growth is driven by rising prevalence of neurological disorder, rising focus by pharmaceutical and biotechnology companies.
The global central nervous system (CNS) therapeutics market is undergoing a transformative phase, driven by rising disease prevalence, increased awareness of neurological and psychiatric disorders, and significant advances in pharmaceutical research and technology. CNS disorders, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s, psychiatric conditions like depression and schizophrenia, as well as epilepsy, trauma, and neurovascular diseases, represent some of the most challenging and costly health concerns worldwide. The demand for effective, accessible, and innovative CNS treatments continues to grow at a steady pace as aging populations expand and mental health issues become more visible and openly discussed.
Technological advancements are transforming every stage of the CNS therapeutics value chain from drug discovery to delivery and patient monitoring. Innovations in neuroimaging, biomarker development, artificial intelligence (AI), and big data analytics are enabling more accurate diagnoses, earlier intervention, and personalized treatment pathways. Digital therapeutics, mobile health applications, and wearable medical devices are offering real-time insights into patient behavior and treatment adherence, particularly valuable for managing chronic CNS disorders such as epilepsy and depression. In drug development, computational biology and AI models are accelerating target identification and reducing clinical trial timelines. Additionally, progress in nanotechnology and drug delivery systems is helping to overcome the blood-brain barrier, enhancing drug efficacy and safety. The potential to revolutionize CNS care grows significantly as the industry embraces digital health and precision medicine, thereby driving the growth.
Industry Dynamics
Rising Prevalence of Neurological Disorder
The global burden of CNS-related conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, and multiple sclerosis is on the rise, driven by aging populations, sedentary lifestyles, and environmental stressors. According to the World Health Organization, 1 in 3 every patient lives with neurological disorder. This surge in neurological disorders is significantly increasing the demand for advanced therapeutics, diagnostics, and long-term care solutions across all regions, thereby driving the growth of the industry.
Rising Focus by Pharmaceutical and Biotechnology Companies
Pharmaceutical and biotechnology companies are intensifying their focus on developing targeted, disease-modifying therapies, supported by advanced diagnostic tools, artificial intelligence, and neuroimaging technologies. The emergence of personalized medicine, biomarkers, and digital health platforms has further accelerated progress in this complex therapeutic area. According to the Personalized Medicine Coalition, personalized medicine topped the new drug approval by FDA in 2023. While regulatory challenges, high R&D costs, and the intricate nature of the blood-brain barrier continue to pose barriers, industry players are adopting strategic collaborations, licensing agreements, and fast-track development routes to bring new treatments more efficiently, thereby driving the growth.
Segmental Insights
Disease Analysis
The mental health segment accounted for 26.15% share during the forecast period driven by a global rise in psychiatric conditions such as depression, anxiety, bipolar disorder, and schizophrenia. Increasing awareness, reduced stigma, and better access to mental health services have contributed to higher diagnosis and treatment rates. Governments and healthcare systems are investing more in mental health infrastructure and support programs. Additionally, the development of novel therapies with fewer side effects and improved efficacy has boosted patient adherence. The demand for CNS therapeutics is rising as mental health continues to be a growing concern worldwide, thereby driving the segment growth.
The neurovascular disease segment recorded USD 23.69 billion in 2024 driven by the rising prevalence of strokes, aneurysms, and related vascular conditions, especially among the elderly. Lifestyle changes, hypertension, and diabetes are major risk factors contributing to the increase in cases. Advances in diagnostic imaging services, early intervention, and minimally invasive treatments have improved patient outcomes. Moreover, ongoing research into neuroprotective agents and clot-dissolving drugs is expanding therapeutic options. Public health campaigns promoting stroke awareness and rapid response further fuels the demand. The demand for neurovascular therapies is expected to grow steadily as life expectancy rises, thereby driving the segment growth.
By Drug Class Analysis
The pain reliever segment accounted for 31.06% market share in 2024 as they are widely used to manage chronic and acute neurological pain. Conditions such as migraines, neuropathic pain, and post-surgical discomfort often require long-term pain management. The demand for both opioid and non-opioid pain medications continue to grow, despite regulatory scrutiny. Innovations in non-addictive pain relief options are attracting strong interest from pharmaceutical companies. The demand for pain relievers is rising as more patients seek effective and safer alternatives for managing CNS-related pain, thereby driving the segment growth.
By Distribution Channel Analysis
The hospital pharmacy segment accounted USD 55.43 billion revenue in 2024 as many CNS treatments, especially for severe mental health or neurovascular conditions, are administered or initiated in hospital settings under close medical supervision. Hospitals further offer access to specialized neurologists and psychiatrists, ensuring accurate diagnosis and personalized treatment plans. Furthermore, critical medications that require controlled storage or monitoring, such as injectable biologics or high-potency drugs, are more safely and efficiently distributed through hospital pharmacies. This makes them a crucial node in the CNS treatment ecosystem, thereby driving the segment growth.
Regional Analysis
Central Nervous System Therapeutics Market in North America
North America central nervous system therapeutics market accounted for 40.24% global share in 2024 driven by advanced healthcare infrastructure, high healthcare spending, and widespread awareness of neurological and mental health conditions. The region benefits from early adoption of innovative drugs and strong support for clinical research. A growing elderly population and rising incidence of Alzheimer’s and Parkinson’s further fuel demand. Pharmaceutical giants and biotech firms in this region actively engage in partnerships and FDA fast-track approvals, making North America a hub for CNS drug development and commercialization, thereby driving the growth in North America.
Central Nervous System Therapeutics Market in US
The US central nervous system therapeutics market is projected to reach USD 83.86 billion by 2034. High prevalence of mental health disorders, increasing diagnosis rates, and strong government focus on mental health care reform drives this growth. The presence of major pharmaceutical companies and robust R&D investment enables rapid innovation and access to new therapies. Additionally, favorable insurance coverage and a large base of neurologists and psychiatrists ensure widespread treatment access. Public awareness campaigns and advocacy for mental health further play a key major in the rising demand for CNS medications across the country, thereby driving the growth.
Central Nervous System Therapeutics Market in Asia Pacific
The Asia Pacific central nervous system therapeutics market recorded USD 25.12 billion revenue in 2024, due to its large population, rising healthcare investment, and increasing awareness of neurological disorders. Urbanization, stress, and aging populations are contributing to higher rates of mental and neurodegenerative diseases. Countries such as India, Japan, and South Korea are expanding healthcare infrastructure and adopting more advanced treatment options. Additionally, government initiatives to improve mental health services and growing pharmaceutical manufacturing capabilities are attracting global players to invest in the region, driving further expansion in Asia Pacific.
Central Nervous System Therapeutics Market in China
The China central nervous system therapeutics market accounted for 37.91% regional share in 2024, driven by a large patient base, increased healthcare spending, and government focus on mental health. The country is facing a growing burden of mental health issues and neurodegenerative diseases due to urban stress, lifestyle changes, and aging. Policy reforms to integrate mental health into primary care and expanded reimbursement coverage are improving access to treatment. Domestic pharmaceutical companies are further increasing their presence in CNS drug development, while partnerships with international firms are helping introduce advanced therapies, thereby driving the growth of industry in China.
Central Nervous System Therapeutics Market in Europe
The Europe central nervous system therapeutics market accounted for 25.08% share in 2024, driven by well-established healthcare systems, high awareness levels, and strong government support for mental health and neurological care. The region benefits from advanced research capabilities and early access to innovative drugs through the European Medicines Agency (EMA). Rising cases of Alzheimer’s, Parkinson’s, and depression, in aging populations are driving demand for effective CNS therapies. Collaborative research initiatives across EU nations and increasing focus on reducing stigma around mental health are further boosting treatment adoption. Moreover, Europe further serves as a key hub for clinical trials and regulatory innovation, thereby driving the expansion in region.
Central Nervous System Therapeutics Market in Germany
The Germany central nervous system therapeutics market recorded USD 6.09 billion revenue in 2024, driven by its robust healthcare infrastructure, high R&D investment, and growing focus on mental health. The country has seen a rise in neurological disorders among its aging population, prompting increased demand for both innovative and generic CNS medications. Government-backed health insurance and reimbursement schemes ensure strong access to treatment. Additionally, Germany's strong pharmaceutical manufacturing base and academic research institutions foster development and distribution of CNS therapies. Public campaigns on mental health awareness and early diagnosis initiatives are further helping drive patient engagement, thereby driving the growth in Germany.
Key Players & Competitive Analysis
The Central Nervous System (CNS) therapeutics market is highly competitive, with key players leveraging innovation and strategic collaborations to gain market share. Biogen Inc. and Eli Lilly dominate the neurodegenerative disorders space, particularly Alzheimer's and multiple sclerosis. Johnson & Johnson, Pfizer, and Merck maintain strong CNS portfolios through R&D and acquisitions. Novartis and Takeda focus on rare neurological conditions and advanced biologics. AstraZeneca is expanding its CNS pipeline through immuno-neurology. Otsuka and Teva lead in psychiatric treatments, notably schizophrenia and depression, with Otsuka’s partnership-driven model proving successful. Neuraxpharm, a specialty CNS firm, offers a competitive edge in Europe through generics and niche therapies. Strategic moves, such as licensing deals and AI-based drug discovery, are reshaping the landscape. As the demand for CNS therapies grows with aging populations, these companies are intensifying efforts in precision medicine and novel delivery platforms to strengthen their competitive positions.
Key Players
- AstraZeneca plc
- Biogen Inc.
- Eli Lilly and Company
- Johnson & Johnson
- Merck & Co., Inc.
- Neuraxpharm
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd
- Pfizer Inc.
- Takeda Pharma Company Ltd
- Teva Pharmaceutical Industries Ltd.
Industry Developments
May 2025: Biogen Inc. and City Therapeutics, Inc., a privately held biopharmaceutical company that is pioneering the future of RNA interference (RNAi)-based medicine, announced a strategic partnership to develop select innovative RNAi therapeutics.
January 2025: Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ai-BrainScience Inc. announce that MIREVO, a program for neuropsychological testing to support medical treatment of dementia, will be the first Software as a Medical Device (SaMD) in the field of dementia to receive national health insurance coverage on January 1, 2025. Marketing of the product in Japan began today.
May 2025: Eli Lilly and firm ("Lilly") and SiteOne Therapeutics, Inc. ("SiteOne"), a private biotechnology firm researching small molecule sodium channel inhibitors to treat pain and other neuronal hyperexcitability disorders, announced a definitive agreement for Lilly to acquire SiteOne.
April 2025: Merck, known as MSD outside of the United States and Canada, has announced the start of construction on a USD 1 billion, 470,000-square-foot cutting-edge biologics centre of excellence in Wilmington, Delaware.
Central Nervous System Therapeutics Market Segmentation
By Disease Outlook (Revenue, USD Billion, 2020–2034)
- Neurovascular Diseases
- CNS Trauma
- Mental Health
- Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson's Disease
- Multiple Sclerosis
- Huntington’s Disease
- Amyotrophic Lateral Sclerosis
- Others
- Infectious Diseases
- CNS Cancer
- Others
By Drug Class Outlook (Revenue, USD Billion, 2020–2034)
- Anesthetics
- Anticonvulsants
- Antiemetic
- CNS Stimulants
- Pain Relievers
- Others
By Distribution Channel Outlook (Revenue, USD Billion, 2020–2034)
- Hospital Pharmacy
- Retail Pharmacy
- Other
By Regional Outlook (Revenue, USD Billion, 2020–2034)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Central Nervous System Therapeutics Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2024 |
USD 123.39 Billion |
|
Market Size in 2025 |
USD 131.81 Billion |
|
Revenue Forecast by 2034 |
USD 265.54 Billion |
|
CAGR |
7.6% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 123.39 billion in 2024 and is projected to grow to USD 256.54 billion by 2034.
The global market is projected to register a CAGR of 7.6% during the forecast period.
North America dominated the market share in 2024.
A few of the key players in the market are AstraZeneca plc; Biogen Inc.; Eli Lilly and Company; Johnson & Johnson; Merck & Co., Inc.; Neuraxpharm; Novartis AG; Otsuka Pharmaceutical Co., Ltd; Pfizer Inc.; Takeda Pharma Company Ltd; Teva Pharmaceutical Industries Ltd.
The mental health segment dominated the market share in 2024.
The hospital pharmacy segment is expected to witness the fastest growth during the forecast period.
© 2025 Polaris Market Research and Consulting. All rights reserved
